 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TCR2 Therapeutics Inc. (NASDAQ:TCRR Get Rating) major shareholder Kevin C. Tang bought 50,000 shares of the companys stock in a transaction on Thursday, May 25th. The stock was bought at an average price of $1.72 per share, for a total transaction of $86,000.00. Following the completion of the ...

Kevin C. Tang Acquires 50,000 Shares of TCR2 Therapeutics Inc. (NASDAQ:TCRR) Stock

TCR2 Therapeutics Inc. (NASDAQ:TCRR Get Rating) major shareholder Mpm Asset Management Llc sold 70,170 shares of the companys stock in a transaction that occurred on Monday, May 22nd. The stock was sold at an average price of $1.88, for a total value of $131,919.60. Following the transaction, the ...

Mpm Asset Management Llc Sells 70,170 Shares of TCR2 Therapeutics Inc. (NASDAQ:TCRR) Stock

TCR2 Therapeutics Inc. (NASDAQ:TCRR  Get Rating) has earned a consensus rating of Hold from the eight ratings firms that are currently covering the company, Marketbeat reports. Six analysts have rated the stock with a hold rating and two have issued a buy rating on the company. ...

TCR2 Therapeutics Inc. (NASDAQ:TCRR) Given Consensus Rating of "Hold" by Brokerages

TCR2 Therapeutics Inc. (NASDAQ:TCRR Get Rating) has received an average rating of Hold from the eight analysts that are presently covering the firm, Marketbeat.com reports. Six equities research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the ...

Analysts Set TCR2 Therapeutics Inc. (NASDAQ:TCRR) PT at $3.57

TCR2 Therapeutics Insider Trades Send a Signal

TCR2 Therapeutics Inc. (NASDAQ:TCRR  Get Rating) major shareholder Kevin C. Tang bought 57,073 shares of the companys stock in a transaction on Monday, May 8th. The stock was bought at an average cost of $1.95 per share, for a total transaction of $111,292.35. Following the completion ...

Kevin C. Tang Acquires 57,073 Shares of TCR2 Therapeutics Inc. (NASDAQ:TCRR) Stock

Mizuho Securities analyst Mara Goldstein maintained a Hold rating on TCR2 Therapeutics (TCRR Research Report) today and set a price target of $2.... Mizuho Securities analyst Mara Goldstein maintained a Hold rating on TCR2 Therapeutics (TCRR &#8211...

TCR2 Therapeutics (TCRR) Receives a Hold from Mizuho Securities

CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR) (TCR2 or the Company), a clinical-stage cell therapy company with a pipeline of novel next-generation T cell therapies for patients suffering from solid tumors, today announced financial results for the first ...

TCR2 Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

TCR2 Therapeutics Inc. (NASDAQ:TCRR  Get Rating) major shareholder Kevin C. Tang acquired 166,823 shares of the firms stock in a transaction on Friday, May 5th. The stock was bought at an average price of $1.92 per share, with a total value of $320,300.16. Following the completion of ...

TCR2 Therapeutics Inc. (NASDAQ:TCRR) Major Shareholder Purchases $320,300.16 in Stock

CAMBRIDGE, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the Compensation Committee of the Board of Directors of TCR2 approved ...

TCR2 Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

TCR2 is a discovery stage pharmaceutical company focused on engineering T cells for cancer therapy. The company's vast expertise in T cell engagement and a deep understanding of T cell receptor biology enabled the creation of a novel first-in-class approach that is highly differentiated from CAR-T cells and from T cells engineered to express defined TCR alpha/beta chains. TCR2 was founded by Dr. Patrick Baeuerle and MPM Capital. It has scientific operations in Kendall Square, Cambridge, Massachusetts to leverage best-in-class technologies and nucleate top-tier academic laboratories around the world.

Watchers	891
52-Wk Low	$0.821
52-Wk High	$3.88

Market Cap	$58.11M
Volume (M)	460,705.00
52-Wk High	$3.88
52-Wk Low	$0.821

Current Price	$1.51
Prev Close	$1.57
Open	$1.59
Dividend Yield	0.00%
50-Day Moving Average	$1.69
Beta	1.36
Avg. Volume	459,385.64
PE Ratio	-0.35

52-Week High	$3.88
52-Week Low	$0.821
Market Capitalization	$58.11M
EPS	-$4.20
Price to Book	0.57
Revenue Per Employee	N/A
Enterprise Value/EBITDA	0.36

TCRR Tcr2 Therapeutics Inc

About

Feed

News

Earnings

Fundamentals